Fax	ed prescriptions will only be	accepted from a prescriber. Par	tients must bring an original prescription	to the pharmacy, and o	cannot fax these referr	al forms to Senderra.	
		Psoriatic Arthritis Enrollment Form	Prescriber:			NPI:	
		I - Z	Supervising Physician:			NPI:	
		Physician Offices Call:	Address:			Tax ID:	
SEND	ERRA	855-460-7928					
Specialty	Pharmacy	Fax: 888-777-5645	Phone:		Fax:		
3712 E. Plano Park Plano, TX 75074	way, Ste. 200	Contact:					
This prescription form is to be sent & received via fax							
Name:		PATIENT INFORMATION  M D F D Trans M D Trans F D Other DOB: ,			SS#:		
Street:		City:		State:		ZIP:	
Phone:		Alt. Phone:	'			Wt.: Ht.:	
Filotie.		Li English Li Spanish Li Other:					
PRESCRIPTION  Has patient received a loading dose/starter kit?  Yes Start Date:							
Has patient receive	ed a loading dose/star	ter kit? Lives Start Date:	//Directions		ome 🗀 Doctor's C	Office U Other:	Refills
. 3	_	INTRAVENOUS (IV):					
Orencia <sup>®</sup>	250 mg Vials	☐ INITIAL: Infuse mg via IV at week 0, 2, and 4 (Quantity: QS 3 doses) ☐ MAINTENANCE: Infuse mg via IV every 4 weeks (Quantity: QS 1 dose)					
	☐ Pre-filled Syringe☐ ClickJect ™	SUBCUTANEOUS (SQ): ☐ Inject 125mg SQ once weekly (Quantity: 4)					
Otezla <sup>®</sup>	Otezla®						
Rinvoq®	30 mg Tablets 15 mg Tablets	□ Take 30 mg PO twice daily (Quantity: 60) □ Take 15 mg PO once daily (Quantity: 30)					
•	☐ SmartJect® (Pen)	☐ Inject 50 mg SQ once a month (Quantity: 1)					
Simponi®	Pre-filled Syringe						
Skyrizi <sup>®</sup>	Pen Pre-filled Syringe	☐ INITIAL: Inject 150 mg SQ at weeks 0 & 4 (Quantity: 1 plus 1 refill) ☐ MAINTENANCE: Inject 150 mg SQ every 12 weeks (Quantity: 1)					
	☐ Pre-filled Syringe	□ INITIAL: Inject 45 mg SQ at weeks 0 & 4 (Quantity: 2) □ MAINTENANCE: Inject 45 mg SQ every 12 weeks (Quantity: 1) □ INITIAL: Inject 90 mg SQ at weeks 0 & 4 (Quantity: 2) □ MAINTENANCE: Inject 90 mg SQ every 12 weeks (Quantity: 1)					
Stelara®	Weight						
	Required:						
Taltz®		□INITIAL: Inject 160 mg (2 x 80 mg) SQ at week 0 (Quantity: 2) □MAINTENANCE: Inject 80 mg SQ every 4 weeks (thereafter) (Quantity: 1)					
		STARTING: Inject 160 mg (2 x 80 mg) SQ at week 0, then begin first induction dose 80 mg (1 x 80 mg) 2 weeks					
	☐ Auto Injector ☐ Pre-filled Syringe	later (week 2) (Quantity: 3)					
		DINDUCTION: Inject 80 mg SQ every 2 weeks (weeks 4-10) (Quantity: 2 plus 1 refill)					
		MAINTENANCE: Injection	□ FINAL INDUCTION: Inject 80 mg SQ (week 12) (Quantity: 1) □ MAINTENANCE: Inject 80 mg SQ every 4 weeks (thereafter) (Quantity: 1)				
	Pen						
Tremfya®	One-Press Injector Pre-filled Syringe	MAINTENANCE: Inject 100 mg SQ at week 0 & 4 (Quantity: 1)					
Volion <b>-</b> ®	, 0	☐ Take 5 mg PO twice	daily (Quantity: 60)				
Xeljanz® Xeljanz® XR	5 mg Tablets 11 mg Tablets	☐ Take 11 mg PO once					
		, ,	MEDICAL INFORMATION			'	
***PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY***							
PREVIOUS THERA  Methotrexate	APIES: Trie □ (	d & Failed (Duration):	Not Tolerated □	:	Conti	raindication:	
Sulfasalazine		)					
	\_		Ē				_
Enbrel	- Naproxen / Nieve — (						
Humira	Humira						_
□ Humira		)	i i				
L40.50 Arthropathic Psoriasis, Unspecified (Psoriatic Arthritis)							
L40.59 Other Psoriatic Arthropathy							
Date of Diagnosis: / / Allergies:							
Active TB is ruled out:							
, additional Cliffical II	normation.		IN IEGELOW TO A WAY				
INJECTION TRAINING  ☐ Patient has received pen and injection training ☐ Physician's office to provide injection training ☐ Senderra to coordinate injection training							
PRESCRIBER SIGNATURE  To Prescriber: By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription insurance							
companies, and co-pay assistance foundations.							
Prescriber:					Date:		
CONFIDENTIALITY NOTICE  IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named							
addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.							